Most of the online weight-loss market does not sell Wegovy or Zepbound. It sells compounded semaglutide and compounded tirzepatide - products made by compounding pharmacies that contain the same active ingredient but are not the same medicine in any regulatory sense. Understanding that difference is the difference between an informed purchase and an accidental one.
What “compounded” actually means
A compounded drug is prepared by a pharmacy for a specific patient, traditionally to solve a problem the commercial product cannot: an allergy to a dye, a dose that is not manufactured, a patient who cannot swallow tablets. Compounding is a legitimate and long-standing part of pharmacy practice.
What compounding is not is a generic. A generic drug is approved by the FDA after demonstrating bioequivalence to the brand. A compounded drug goes through no such process. The FDA does not review it for safety, does not review it for effectiveness, and does not review the facility's manufacturing quality the way it does for an approved product. Every honest compounded GLP-1 provider says this somewhere on its site. The dishonest ones say it in eight-point type at the bottom.
| Brand-name (Wegovy, Zepbound, Foundayo) | Compounded semaglutide / tirzepatide | |
|---|---|---|
| FDA approval | Yes - reviewed for safety, efficacy and manufacturing | No - not reviewed on any of the three |
| Clinical trial evidence | Phase 3 programmes with thousands of participants | None for the compounded product itself |
| Consistency between batches | Manufactured to approved specifications | Depends entirely on the pharmacy |
| Is it a generic? | n/a | No. Generics are FDA-approved; compounds are not |
| Typical self-pay cost | $149-$499/month | $118-$299/month |
| Who regulates it | FDA | 503A: state boards of pharmacy. 503B: FDA-registered outsourcing facility |
Why compounded GLP-1s exist at all
Federal law generally prohibits compounding a copy of a commercially available approved drug. The exception that built this entire industry is shortage: when the FDA lists a drug as being in shortage, compounders may prepare copies of it. Semaglutide and tirzepatide were both in shortage for extended periods as demand outstripped manufacturing, and a very large telehealth market grew in that window.
Those shortages have since been resolved, and the regulatory position tightened accordingly. The FDA has run successive rounds of enforcement, including a batch of 30 warning letters to telehealth companies in March 2026 over false or misleading claims about compounded GLP-1 products. The agency named two specific problems: claims implying the compounded product is the same as the FDA-approved one, and marketing products under the telehealth firm's own brand name in a way that obscures who actually compounded them.
This is not abstract. In a further round dated 8 June 2026, the FDA wrote to more telehealth firms on the same grounds - and four providers reviewed on this site were among them. The letters are specific and worth reading if you want to understand what the regulator objects to: in each case the compounded vials pictured on the company's website carried the company's own name or logo, “suggesting [the company] is the compounder of those drugs when in fact it is not”. Two of the letters also cite the phrase “FDA-licensed” or “FDA approved” applied to a pharmacy. The FDA's position on that is worth committing to memory: compounding facilities “are not ‘FDA-approved’ or ‘FDA-licensed’ entities”, and no such designation exists.
We link each letter from the relevant review and exclude those four providers from our rankings. See how we rank the rest.
If you recognise this pattern, take it seriously
The price argument has largely collapsed
The original case for compounded GLP-1 was overwhelming: brand-name semaglutide at over $1,000 a month against a compounded copy at $200. That gap no longer exists in the same form. Novo Nordisk now sells brand-name Wegovy through its own pharmacy from $149 a month for the pill and $199 for the pen, and Eli Lilly sells Foundayo from $149 a month self-pay through LillyDirect.
Against those numbers, a compounded plan at $199 to $299 a month is not a bargain. It is the same money or more for a product with no FDA review. There are still cheaper compounded plans - some start around $118 to $162 a month - and for people at whom that difference genuinely matters, the trade-off is real. But it should be a considered trade-off, not an assumption.
How to vet a compounded provider
If you decide compounded is right for you, the difference between providers is almost entirely about disclosure. Ask these five questions and insist on written answers:
- •Which pharmacy compounds it, and under which licence? A provider that names its pharmacy - and says whether it is 503A or 503B - has given you something checkable. “A licensed US pharmacy” is not an answer. We tested this: every pharmacy named by a provider reviewed here - Rush, Clover, VialsRx, Greenwich, Belmar, Strive, The Pharmacy Hub, Foothills, Precision Compounding, Red Rock, Triad Rx and Beaker - resolves to a real, operating pharmacy business. Naming one is not a formality; it is the difference between a claim you can check and a claim you cannot.
- •Can I have the Certificate of Analysis for my batch? Good compounders test each batch for potency and purity and will hand over the certificate on request.
- •Does the price change as my dose increases? Tirzepatide climbs from 2.5 mg to 15 mg. A per-milligram provider will multiply your bill along the way.
- •What happens to my money if the provider declines to prescribe? The better ones refund in full. Some keep the consultation fee regardless.
- •Is it shipped cold? Some providers ship temperature-controlled and say so. Others state that they do not ship refrigerated products at all.
503A and 503B are not the same thing, and it matters
Providers use both terms, often interchangeably. They are not interchangeable. A 503A pharmacy compounds for an individual patient against a prescription. It is licensed by a state board of pharmacy. The FDA does not register it, does not routinely inspect it, and does not hold it to the CGMP manufacturing standards that apply to drug makers. A 503B outsourcing facility registers with the FDA, can compound in batches without patient-specific prescriptions, is subject to FDA inspection, and must meet CGMP.
The FDA publishes the complete list of registered 503B facilities, and it is short: 96 facilities in the entire country as of 30 July 2026. We checked every pharmacy named by a provider reviewed on this site against that list. None of them appears on it.
What that actually means
How to check a pharmacy yourself
If a provider names its pharmacy and gives a licence number, you can verify it in about two minutes. Every state board of pharmacy runs a public licence lookup. We did this with the one provider on this site specific enough to allow it - Trimi Health publishes “VialsRx (Texas Board of Pharmacy #35264)”. The Texas board's database returns that licence as active until February 2028, classed as Community Sterile Compounding, with no prior disciplinary orders. The licensed name on the record differs from the trading name, which is ordinary, and the address matches the pharmacy's own site.
That is what a checkable claim looks like. Search “[state] board of pharmacy license verification”, enter the number, and read the status, the expiry, the class of pharmacy and the disciplinary history. If a provider will not tell you which pharmacy or give you a number, there is nothing to check - and after the FDA's warning letters, that is the question worth asking first.
Why the licence number matters more than the name
A word on microdosing
A growing number of compounded providers sell “microdose” GLP-1 plans - fixed, low doses that never titrate to therapeutic levels, marketed for gentler or cosmetic weight loss. There is no trial evidence for this. Every weight-loss figure the category quotes comes from full therapeutic dosing of an approved product. Microdosing may well suit people who cannot tolerate full doses, but it should be sold as what it is rather than dressed in numbers it did not earn.
Where to go from here
- •Best compounded GLP-1 providers - ranked on disclosure, not on price alone
- •Best online GLP-1 providers - brand-name and compounded together
- •NovoCare Pharmacy review - the manufacturer's own direct-to-consumer pricing
- •What GLP-1 medication actually costs